Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform, Lowers Price Target to $29

Benzinga Newsdesk www.benzinga.com Negative 93.3%

Neg 93.3% Neu 0% Pos 0%

Leerink Partners analyst Mike Kratky downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform and lowers the price target from $31 to $29.